SCHEMBL25792007

SCHEMBL25792007

CCn1cc(Cl)nc1-c1ccc(CBr)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.39
NR1H3 Q13133 2/20 0.33
USP1 O94782 2/20 0.32
LMNA P02545 1/20 0.31
GFER P55789 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
BAZ2A Q9UIF9 1/20 0.31
SPNS2 Q8IVW8 1/20 0.31
ALDH1A1 P00352 5/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31
GAA P10253 2/20 0.30
MAPT P10636 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25792009 0.84 BRD4 (0.39) BRD4NR1H3USP1
SCHEMBL25792044 0.84 BRD4 (0.35) BRD4NR1H3USP1SPNS2ALDH1A1
SCHEMBL25791868 0.79 USP1 (0.46) USP1
SCHEMBL25792010 0.73 ADORA2A (0.47) LMNATDP1ALDH1A1MEN1KMT2A
SCHEMBL860536 0.71 ALDH1A1 (0.30) ALDH1A1
SCHEMBL28223263 0.68
SCHEMBL25792045 0.68 BRD4 (0.35) BRD4LMNASPNS2MEN1KMT2A
SCHEMBL30320360 0.67 PTGS2 (0.37) NR1H3USP1CYP4F2CYP4A11NR1H2
SCHEMBL29962831 0.67 GRM5 (0.36) BRD4ALDH1A1
SCHEMBL25288162 0.67 NR1H3 (0.43) NR1H3SMN1; SMN2CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
EP-4161494-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 BRD4 566/4885NR1H3 3274/4885USP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.